Ambry Genetics ยท 3 hours ago
Rare Disease Account Executive - Missouri
Ambry Genetics is a company specializing in genetic diagnostic testing services, and they are seeking a Rare Disease Account Executive for the Missouri territory. The role focuses on increasing laboratory sales revenue through market penetration and promoting the company's portfolio while managing customer relationships and driving sales to closure.
Health CareHealth DiagnosticsMedical
Responsibilities
Manage a sales territory
Live in the designated territory
Manage and grow business in existing Ambry accounts
Expand menu utilization in existing accounts
Sell genetic diagnostic testing services to new customers
Negotiate and manage contracts
Introduce new testing products
Develop demand for and adoption of new assays
Develop and implement customer-specific action plans
Develop and deliver presentations
Host and assist with trade shows
Manage customer data in the company database
Achieve sales goals
Other duties as assigned
Qualification
Required
3+ years of industry experience selling laboratory services to clinicians and hospitals or medical device sales
Bachelor's Degree and/or combined years of experience required
Skilled in Microsoft Word, Excel, PowerPoint applications
Skilled using a CRM applications such as com or Microsoft CRM
Strong track record of sales success selling a broad portfolio of laboratory testing to different medical specialties
Ability to sell technically complex products
Expertise with demand creation in a large geography
Strengths in networking and relationship development
Strong oral and written communications skills
Some formal sales training experience such as SPIN Selling or PSS
Strong time and territory management skills
Possess and maintain a current, valid driver license unless agreed upon otherwise
Preferred
Bachelor's Degree is highly preferred
Experience with customer base within territory
Company
Ambry Genetics
Ambry leads in clinical genetic diagnostics and genetics software solutions.
Funding
Current Stage
Late StageTotal Funding
unknown2024-11-06Acquired
2017-10-19Series Unknown
Recent News
2025-11-25
Company data provided by crunchbase